Nadar SK - Search Results

1

Ventricular interdependence in hypertension: fact or fiction?

Elsisi IFHA, Tan FSC, Nadar SK, Tayebjee MH. Elsisi IFHA, et al. Among authors: nadar sk. J Hum Hypertens. 2019 Jul;33(7):489-490. doi: 10.1038/s41371-019-0202-2. Epub 2019 Apr 16. J Hum Hypertens. 2019. PMID: 30992513 No abstract available.

2

Managing hypertension during the COVID-19 pandemic.

Nadar SK, Tayebjee MH, Stowasser M, Byrd JB. Nadar SK, et al. J Hum Hypertens. 2020 Jun;34(6):415-417. doi: 10.1038/s41371-020-0356-y. Epub 2020 May 14. J Hum Hypertens. 2020. PMID: 32409727 Free PMC article. No abstract available.

3

Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.

Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY. Tayebjee MH, et al. Among authors: nadar sk. Am J Hypertens. 2004 Sep;17(9):770-4. doi: 10.1016/j.amjhyper.2004.06.023. Am J Hypertens. 2004. PMID: 15363818

4

Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis.

Patel JV, Lim HS, Nadar S, Tayebjee M, Hughes EA, Lip GY. Patel JV, et al. J Hypertens. 2006 Jan;24(1):117-21. doi: 10.1097/01.hjh.0000198034.09010.bc. J Hypertens. 2006. PMID: 16331109

5

Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.

Tayebjee MH, Karalis I, Nadar SK, Beevers DG, MacFadyen RJ, Lip GY. Tayebjee MH, et al. Among authors: nadar sk. Am J Hypertens. 2005 Mar;18(3):325-9. doi: 10.1016/j.amjhyper.2004.09.014. Am J Hypertens. 2005. PMID: 15797648

6

Tissue inhibitor of metalloproteinse-1 is a marker of diastolic dysfunction using tissue doppler in patients with type 2 diabetes and hypertension.

Tayebjee MH, Lim HS, Nadar S, MacFadyen RJ, Lip GY. Tayebjee MH, et al. Eur J Clin Invest. 2005 Jan;35(1):8-12. doi: 10.1111/j.1365-2362.2005.01438.x. Eur J Clin Invest. 2005. PMID: 15638813

7

Target organ damage in hypertension: pathophysiology and implications for drug therapy.

Nadar SK, Tayebjee MH, Messerli F, Lip GY. Nadar SK, et al. Curr Pharm Des. 2006;12(13):1581-92. doi: 10.2174/138161206776843368. Curr Pharm Des. 2006. PMID: 16729871 Review.

8

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Tayebjee MH, et al. Am J Hypertens. 2004 Sep;17(9):764-9. doi: 10.1016/j.amjhyper.2004.05.019. Am J Hypertens. 2004. PMID: 15363817 Clinical Trial.

9

Inflammation and hypertension: more evidence but is there anything new?

Nadar SK, Goyal D. Nadar SK, et al. J Hum Hypertens. 2021 Jul;35(7):561-563. doi: 10.1038/s41371-020-00463-7. Epub 2020 Dec 7. J Hum Hypertens. 2021. PMID: 33288857 No abstract available.

10

The heart in hypertension.

Nadar SK, Lip GYH. Nadar SK, et al. J Hum Hypertens. 2021 May;35(5):383-386. doi: 10.1038/s41371-020-00427-x. Epub 2020 Oct 12. J Hum Hypertens. 2021. PMID: 33046827 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

107 results

Search Page